Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris》.pdfVIP

Atherosclerosis 148 (2000) 317–326 locateatherosclerosis Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris Oscar Perez-Mendez a, Eric Bruckert b, Guido Franceschini d, Nathalie Duhal c, Brigitte Lacroix c, Jean-Paul Bonte c, Cesare Sirtori d, Jean-Charles Fruchart a, Ge´rard Turpin a, Ge´rald Luc a,* a Department of Atherosclerosis, SERLIA and INSERM U325, Institut Pasteur de Lille, 1, rue du Professeur Calmette, 59019 Lille cedex, France b Department of Endocrinology -Metabolism, Hoˆpital de la Pitie´, Paris, France c Centre Uniersitaire de Mesures et d ’Analyses, Faculte´ de Pharmacie, Uniersite´ de Lille II, Lille, France d Centro E. Grossi Paoletti, Istituto di Scienze Farmacologiche, Milan, Italy Received 27 May 1999; received in revised form 27 May 1999; accepted 29 June 1999 Abstract ApoAI Milano (AI ) and apoAI Paris (AI ) are mutant forms of apoAI in which cysteine is substituted for arginine at residues M P 173 and 151 respectively leading to the formation of homodimers and heterodimers with apoAII. Heterozygous subjects with these mutants are characterized by low levels of plasma HDL cholesterol and apoAI. The present study analyzed the metabolism of the different complexes of apoAI in three subjects, two AI and one AI , using a primed-constant infusion of trideuterated leucine. M